Drug assessment at a glance: A26-37[1] **Depemokimab (chronic rhinosinusitis with nasal polyps)**

25 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-37. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Add-on therapy for adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control
Intervention	depemokimab as an add-on therapy
Comparator	dupilumab or omalizumab or mepolizumab, each in combination with intranasal corticosteroids (budesonide or mometasone furoate)
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects	Informative value of the effects
Mortality	ø	–
Morbidity	ø	–
Symptoms	ø	–
Health-related quality of life	ø	–
Side effects	ø	–
	ø No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: no advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No relevant studies were available.

- In the randomized, double-blind, multicentre ANCHOR-1 and ANCHOR-2 studies, patients were generally not permitted to take the biologics specified as the comparator therapy (dupilumab, omalizumab or mepolizumab). The treatment in the comparator arms of both studies therefore did not correspond to the comparator therapy.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Depemokimab (chronische Rhinosinusitis mit Nasenpolypen); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 11.08.2026]. URL: https://doi.org/10.60584/A26-37.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Depemokimab (Chronische Rhinosinusitis mit Nasenpolypen) [online]. 2026 [Accessed: 11.08.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1333/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-37.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de